Since the effect of DPP4 inhibitor on hemoglobin was greater in patients with more advanced DKD, follow up studies that focus on stages 3b to 5, as well as on any potential interaction with the use of SGLT2 inhibitor, would be particularly valuable. This evidence concerns the gene DPP4 and diabetic kidney disease.